Lansoprazole Aurobindo

Lansoprazole, the active ingredient in Lansoprazole Aurobindo, is a proton pump inhibitor presented as a dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal conditions in adults. GNH USA supplies Lansoprazole Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastroesophageal reflux disease (GERD): reduces acid exposure and relieves heartburn and regurgitation symptoms. - Erosive esophagitis: promotes healing of inflamed esophageal tissue by lowering gastric acidity. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence by suppressing acid secretion. - Helicobacter pylori eradication: used in combination regimens to improve bacterial clearance.

Adverse reactions may occur with Lansoprazole use.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: feeling of queasiness, usually mild. - Abdominal pain: discomfort in the stomach region.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate medical attention. - Low magnesium levels: may cause muscle cramps, irregular heartbeat, or seizures. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea and abdominal pain.

Before initiating therapy, consider the following safety measures.

- Assess renal function: adjust use in patients with significant impairment. - Monitor magnesium levels: especially during prolonged treatment. - Evaluate for Helicobacter pylori infection: confirm eradication after therapy. - Use with caution in elderly patients: increased risk of fractures and renal issues. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lansoprazole may alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole: reduced antifungal absorption. - Atazanavir: decreased antiviral efficacy. - Clarithromycin: increased risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Clopidogrel: diminished antiplatelet effect. - Digoxin: potential increase in serum levels. - Methotrexate: enhanced toxicity, especially at high doses.